ID   Ishikawa
AC   CVCL_2529
SY   ISHIKAWA; ISHI
DR   BTO; BTO:0003041
DR   EFO; EFO_0005718
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0364
DR   BioSample; SAMN03471030
DR   CCRID; 1101HUM-PUMC000686
DR   Cell_Model_Passport; SIDM00038
DR   ChEMBL-Cells; CHEMBL3307675
DR   ChEMBL-Targets; CHEMBL614649
DR   Cosmic; 713475
DR   Cosmic; 713499
DR   Cosmic; 809129
DR   Cosmic; 846174
DR   Cosmic; 1070811
DR   Cosmic; 1152553
DR   Cosmic; 1176597
DR   Cosmic; 1177618
DR   Cosmic; 1241344
DR   Cosmic; 1622902
DR   Cosmic; 1696753
DR   Cosmic; 2030475
DR   Cosmic; 2464666
DR   Cosmic; 2646616
DR   Cosmic; 2702440
DR   ECACC; 99040201
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS228AAA
DR   ENCODE; ENCBS229AAA
DR   ENCODE; ENCBS230AAA
DR   GEO; GSM374972
DR   GEO; GSM375431
DR   GEO; GSM827370
DR   GEO; GSM1008593
DR   GEO; GSM1008594
DR   GEO; GSM1669941
DR   GEO; GSM3161714
DR   GEO; GSM3161715
DR   IARC_TP53; 1112
DR   LINCS_HMS; 50018
DR   LINCS_LDP; LCL-1497
DR   PharmacoDB; Ishikawa_667_2019
DR   Progenetix; CVCL_2529
DR   TOKU-E; 3966
DR   Wikidata; Q54898281
RX   DOI=10.1007/978-4-431-53981-0_2;
RX   PubMed=4031568;
RX   PubMed=12703541;
RX   PubMed=15053063;
RX   PubMed=15901131;
RX   PubMed=20215515;
RX   PubMed=20218740;
RX   PubMed=20944090;
RX   PubMed=22710073;
RX   PubMed=23255909;
RX   PubMed=27397505;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/Ishikawa_Crawford_protocol.pdf
CC   Part of: ENCODE project common cell types; tier 3.
CC   Population: Japanese.
CC   Doubling time: 36 hours (at 9th passage), 29 hours (at 40th passage), 27 hours (at 50th passage) (DOI=10.1007/978-4-431-53981-0_2); 35.14 +- 2.68 hours (PubMed=23255909).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line).
CC   Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line).
CC   Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131).
CC   Omics: Array-based CGH.
CC   Omics: ATAC-seq.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Misspelling: Ischikawaa; Occasionally.
CC   Derived from sampling site: Endometrium.
ST   Source(s): ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 9
ST   D18S51: 13,19
ST   D19S433: 12.2,14
ST   D21S11: 28
ST   D2S1338: 20
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   D8S1179: 12,16
ST   FGA: 21
ST   Penta D: 10,11
ST   Penta E: 11,19
ST   TH01: 9,10
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 31
//
RX   DOI=10.1007/978-4-431-53981-0_2;
RA   Nishida M.;
RT   "Ishikawa cells: opening of in vitro hormone research on endometrial
RT   carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.35-58; Springer; Tokyo (2003).
//
RX   PubMed=4031568;
RA   Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K.;
RT   "Establishment of a new human endometrial adenocarcinoma cell line,
RT   Ishikawa cells, containing estrogen and progesterone receptors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 37:1103-1111(1985).
//
RX   PubMed=12703541; DOI=10.1111/j.1749-0774.2002.tb00105.x;
RA   Nishida M.;
RT   "The Ishikawa cells from birth to the present.";
RL   Hum. Cell 15:104-117(2002).
//
RX   PubMed=15053063;
RA   Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.;
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20218740; DOI=10.1177/153303461000900207;
RA   Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R.,
RA   Zhang W.;
RT   "Genomic characterization of gene copy-number aberrations in
RT   endometrial carcinoma cell lines derived from endometrioid-type
RT   endometrial adenocarcinoma.";
RL   Technol. Cancer Res. Treat. 9:179-189(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23255909; DOI=10.3892/ol.2012.975;
RA   Zhao S.-Z., Li G.-X., Yang L., Li L., Li H.-Y.;
RT   "Response-specific progestin resistance in a newly characterized
RT   Ishikawa human endometrial cancer subcell line resulting from
RT   long-term exposure to medroxyprogesterone acetate.";
RL   Oncol. Lett. 5:139-144(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//